Skip to main content

Table 1 Patient characteristics

From: Evaluation of in vivo labelled dendritic cell migration in cancer patients

Patients

Sex/Age

Pathology

Site of Metastasis

Previous Treatment

i/mDC

HLA

1

M/47

Mel

Liver, mediastinal lymph nodes

IFN

iDC

A1A2B8B35Bw6Cw4Cw7

2

M/52

Mel

Liver

BIOCT

iDC

A3A28B35B53Cw4

3

M/49

Mel

Liver, adrenal glands

No treatment

iDC + mDC

A11A31B14B60Bw6Cw3

4

M/42

Mel

Liver, mediastinal and axillary lymph nodes

BIOCT

iDC+ mDC

A1A9B17Bw4Bw6Cw3Cw4

5

F/49

Mel

Lung, lymph nodes, skin, peritoneum

BIOCT

iDC+ mDC

A1A9B7B44Bw4Bw6Cw4Cw7

6

M/50

Renal ca.

Skin, adrenal glands

BIOCT

mDC

A2A3B7B51Bw4Bw6Cw1Cw7

7

F/52

Mel

Lung, liver

HdIFN + CT

mDC

A3A29B44Bw4

8

M/46

Mel

Abdominal lymph nodes

IFN+BIOCT

mDC

A3A28B21B35Cw4

  1. IFN, alpha interferon; BIOCT, biochemotherapy; CT, chemotherapy; HdIFN, high-dose adjuvant alpha interferon (ECOG 1684)